



**HPTN**

HIV Prevention  
Trials Network



**Imperial College  
London**

# **Estimating the impact of improvements in the HIV care cascade on HIV incidence among men who have sex with men in the US: mathematical modelling for HPTN 078**

**Kate M Mitchell**

**Imperial College London**

**London, UK**

**25<sup>th</sup> July 2017**


## **Enhancing Recruitment, Linkage to Care and Treatment for HIV-Infected Men Who Have Sex with Men (MSM) in the United States**

Trial sites: Atlanta GA, Baltimore MD,  
Birmingham AL, Boston MA

## **Enhancing Recruitment, Linkage to Care and Treatment for HIV-Infected Men Who Have Sex with Men (MSM) in the United States**

Trial sites: Atlanta GA, Baltimore MD,  
Birmingham AL, Boston MA

## Enhancing Recruitment, Linkage to Care and Treatment for HIV-Infected Men Who Have Sex with Men (MSM) in the United States



- 1. Before/during the trial - to estimate levels of viral suppression that must be reached to attain HIV incidence reduction targets**
- 2. After the trial - to estimate reduction in HIV incidence achieved by trial interventions**

1. **Before/during the trial** - to estimate levels of viral suppression that must be reached to attain HIV incidence reduction targets
2. **After the trial** - to estimate reduction in HIV incidence achieved by trial interventions

- 1. Before/during the trial - to estimate levels of viral suppression that must be reached to attain HIV incidence reduction targets**
- 2. After the trial - to estimate reduction in HIV incidence achieved by trial interventions**

- **HIV prevalence: 30% in 2014** (NHBS\*)
- **Virally suppressed: 40% of diagnosed in 2015** (Maryland DHMH)
- **PrEP use: 2.4% in 2014** (NHBS\*)

\*CDC National HIV Behavioral Surveillance



- HIV prevalence: 30% in 2014 (NHBS\*)
- **Virally suppressed: 40% of diagnosed in 2015** (Maryland DHMH)
- PrEP use: 2.4% in 2014 (NHBS\*)

\*CDC National HIV Behavioral Surveillance

- **HIV prevalence: 30% in 2014** (NHBS\*)
- **Virally suppressed: 40% of diagnosed in 2015** (Maryland DHMH)
- **PrEP use: 2.4% in 2014** (NHBS\*)

\*CDC National HIV Behavioral Surveillance

1. How much does the level of viral suppression need to be increased by to **reduce HIV incidence** among Baltimore MSM by 10, 20, 30 or 50% after 2, 5 and 10 years?
2. By how much could HIV incidence be reduced if **US National HIV/AIDS strategy (NHAS) targets** met by 2020:
  - 90% diagnosed
  - 90% of diagnosed retained in care
  - 80% of diagnosed virally suppressed
3. What is the likelihood of **local HIV elimination** among MSM in Baltimore in the next 20 years under current levels of care and if these targets are met?

1. How much does the level of viral suppression need to be increased by to **reduce HIV incidence** among Baltimore MSM by 10, 20, 30 or 50% after 2, 5 and 10 years?
2. By how much could HIV incidence be reduced if **US National HIV/AIDS strategy (NHAS) targets** met by 2020:
  - 90% diagnosed
  - 90% of diagnosed retained in care
  - 80% of diagnosed virally suppressed
3. What is the likelihood of **local HIV elimination** among MSM in Baltimore in the next 20 years under current levels of care and if these targets are met?

1. How much does the level of viral suppression need to be increased by to **reduce HIV incidence** among Baltimore MSM by 10, 20, 30 or 50% after 2, 5 and 10 years?
2. By how much could HIV incidence be reduced if **US National HIV/AIDS strategy (NHAS) targets** met by 2020:
  - 90% diagnosed
  - 90% of diagnosed retained in care
  - 80% of diagnosed virally suppressed
3. What is the likelihood of **local HIV elimination** among MSM in Baltimore in the next 20 years under current levels of care and if these targets are met?


- Deterministic compartmental model
- Sexual HIV transmission

- **Disease progression:** CD4 decline stratified by viral load
- **Risk groups:** age (<25, 25+) x race (black, white)
- **Care cascade:**

- **Disease progression:** CD4 decline stratified by viral load
- **Risk groups:** age (<25, 25+) x race (black, white)
- **Care cascade:**



- **Disease progression:** CD4 decline stratified by viral load
- **Risk groups:** age (<25, 25+) x race (black, white)
- **Care cascade:**



Domain	Examples	Data source
<b>Disease progression</b>	<ul style="list-style-type: none"> <li>Initial CD4 and viral load distribution</li> <li>HIV-related mortality</li> <li>CD4 progression rates</li> </ul>	Published studies: cohorts in North America and Europe
<b>Infection probabilities</b>	<ul style="list-style-type: none"> <li>Per-sex-act transmission probability</li> <li>Relative infectiousness different disease stages</li> </ul>	Published studies: meta analyses, study of Australian MSM
<b>Intervention efficacy</b>	<ul style="list-style-type: none"> <li>Reduction in per-sex-act HIV transmission risk: condoms, ART</li> </ul>	Published studies: clinical trials, meta-analyses
<b>Sexual risk behaviour</b>	<ul style="list-style-type: none"> <li>Number and type of partners</li> <li>Condom use</li> <li>Age and race of partners</li> </ul>	NHBS surveillance data, (eventually 078 trial) <b>Baltimore</b>
<b>Intervention behaviour</b>	<ul style="list-style-type: none"> <li>HIV testing</li> <li>Linkage/dropout from HIV care</li> <li>ART initiation, adherence and dropout</li> </ul>	NHBS surveillance data, clinical cohorts, state health department data, (eventually 078 trial) <b>Baltimore</b>

Domain	Examples	Data source
<b>Disease progression</b>	<ul style="list-style-type: none"> <li>Initial CD4 and viral load distribution</li> <li>HIV-related mortality</li> <li>CD4 progression rates</li> </ul>	Published studies: cohorts in North America and Europe
<b>Infection probabilities</b>	<ul style="list-style-type: none"> <li>Per-sex-act transmission probability</li> <li>Relative infectiousness different disease stages</li> </ul>	Published studies: meta analyses, study of Australian MSM
<b>Intervention efficacy</b>	<ul style="list-style-type: none"> <li>Reduction in per-sex-act HIV transmission risk: condoms, ART</li> </ul>	Published studies: clinical trials, meta-analyses
<b>Sexual risk behaviour</b>	<ul style="list-style-type: none"> <li>Number and type of partners</li> <li>Condom use</li> <li>Age and race of partners</li> </ul>	NHBS surveillance data, (eventually 078 trial) <b>Baltimore</b>
<b>Intervention behaviour</b>	<ul style="list-style-type: none"> <li>HIV testing</li> <li>Linkage/dropout from HIV care</li> <li>ART initiation, adherence and dropout</li> </ul>	NHBS surveillance data, clinical cohorts, state health department data, (eventually 078 trial) <b>Baltimore</b>

Domain	Examples	Data source
<b>Disease progression</b>	<ul style="list-style-type: none"> <li>Initial CD4 and viral load distribution</li> <li>HIV-related mortality</li> <li>CD4 progression rates</li> </ul>	Published studies: cohorts in North America and Europe
<b>Infection probabilities</b>	<ul style="list-style-type: none"> <li>Per-sex-act transmission probability</li> <li>Relative infectiousness different disease stages</li> </ul>	Published studies: meta analyses, study of Australian MSM
<b>Intervention efficacy</b>	<ul style="list-style-type: none"> <li>Reduction in per-sex-act HIV transmission risk: condoms, ART</li> </ul>	Published studies: clinical trials, meta-analyses
<b>Sexual risk behaviour</b>	<ul style="list-style-type: none"> <li>Number and type of partners</li> <li>Condom use</li> <li>Age and race of partners</li> </ul>	NHBS surveillance data, (eventually 078 trial) <b>Baltimore</b>
<b>Intervention behaviour</b>	<ul style="list-style-type: none"> <li>HIV testing</li> <li>Linkage/dropout from HIV care</li> <li>ART initiation, adherence and dropout</li> </ul>	NHBS surveillance data, clinical cohorts, state health department data, (eventually 078 trial) <b>Baltimore</b>

- Observed Baltimore data:
  - HIV prevalence - by age and race (NHBS)
  - MSM demography - age and race (NHBS, census)
  - Care cascade - % retained in care, on ART, virally suppressed (NHBS, Maryland DHMH)

- Observed Baltimore data:
  - **HIV prevalence** - by age and race (NHBS)
  - **MSM demography** - age and race (NHBS, census)
  - **Care cascade** - % retained in care, on ART, virally suppressed (NHBS, Maryland DHMH)

- Observed Baltimore data:
  - **HIV prevalence** - by age and race (NHBS)
  - **MSM demography** - age and race (NHBS, census)
  - **Care cascade** - % retained in care, on ART, virally suppressed (NHBS, Maryland DHMH)

- Observed Baltimore data:
  - HIV prevalence - by age and race (NHBS)
  - MSM demography - age and race (NHBS, census)
  - **Care cascade** - % retained in care, on ART, virally suppressed (NHBS, Maryland DHMH)



1. Defined plausible parameter ranges
2. Sampled parameter ranges randomly 4 million times
3. With each parameter set, simulated HIV epidemic 1984 – 2015
4. Retained parameter sets for which model outputs agree with observed Baltimore data





1. Defined plausible parameter ranges
2. Sampled parameter ranges randomly 4 million times
3. With each parameter set, simulated HIV epidemic 1984 – 2015
4. Retained parameter sets for which model outputs agree with observed Baltimore data

1. Defined plausible parameter ranges
2. Sampled parameter ranges randomly 4 million times
3. With each parameter set, simulated HIV epidemic 1984 – 2015
4. Retained parameter sets for which model outputs agree with observed Baltimore data


1. Defined plausible parameter ranges
2. Sampled parameter ranges randomly 4 million times
3. With each parameter set, simulated HIV epidemic 1984 – 2015
4. Retained parameter sets for which model outputs agree with observed Baltimore data

# Model Fits: HIV prevalence by age and race


**N=299**




## HIV incidence




## % of HIV-infected MSM virally suppressed




## HIV incidence



## % of HIV-infected MSM virally suppressed




## Target: reduce HIV incidence by 10, 20, 30, 50%







## Target: reduce HIV incidence by 10, 20, 30, 50%



## Target: reduce HIV incidence by 10, 20, 30, 50%



## Target: reduce HIV incidence by 10, 20, 30, 50%



If NHAS targets all met in 2020:


90% diagnosed – 90% of diagnosed in care - 80% of diagnosed virally suppressed

---

If NHAS targets all met in 2020:

90% diagnosed – 90% of diagnosed in care - 80% of diagnosed virally suppressed


## Increase in viral suppression in 2020




If NHAS targets all met in 2020:

90% diagnosed – 90% of diagnosed in care - 80% of diagnosed virally suppressed

## Increase in viral suppression in 2020




## Incidence reduction in 2020




If NHAS targets all met in 2020:

90% diagnosed – 90% of diagnosed in care - 80% of diagnosed virally suppressed

## Increase in viral suppression in 2020



## Incidence reduction in 2020



**Meeting NHAS targets: very similar effect to reaching 50% incidence reduction target after 5 yrs**

Likelihood of HIV elimination (HIV incidence  $<0.1\%$  per year) among MSM in Baltimore in the next 20 years:

- under current levels of care: **0**
- when incidence reduction targets are met:

Incidence reduction target:	10%	20%	30%	50%
2 years	0	0	3.5%	-
5 years	0	0	0	0.02%
10 years	0	0	0	0

- when NHAS targets are met:

target:	90% of infected diagnosed	90% of diagnosed in care	80% of diagnosed virally suppressed	All 3 targets
	0	4.64%	0.40%	0.42%



Likelihood of HIV elimination (HIV incidence <0.1% per year) among MSM in Baltimore in the next 20 years:

- under current levels of care: 0
- when incidence reduction targets are met:

Incidence reduction target:	10%	20%	30%	50%
2 years	0	0	3.5%	-
5 years	0	0	0	0.02%
10 years	0	0	0	0

- when NHAS targets are met:

target:	90% of infected diagnosed	90% of diagnosed in care	80% of diagnosed virally suppressed	All 3 targets
	0	4.64%	0.40%	0.42%

Likelihood of HIV elimination (HIV incidence  $<0.1\%$  per year) among MSM in Baltimore in the next 20 years:

- under current levels of care: 0
- when incidence reduction targets are met:

Incidence reduction target:	10%	20%	30%	50%
2 years	0	0	3.5%	-
5 years	0	0	0	0.02%
10 years	0	0	0	0

- when NHAS targets are met:

target:	90% of infected diagnosed	90% of diagnosed in care	80% of diagnosed virally suppressed	All 3 targets
	<b>0</b>	<b>4.64%</b>	<b>0.40%</b>	<b>0.42%</b>

- Large increases in viral suppression are needed to significantly reduce HIV incidence among Baltimore MSM
- Achieving NHAS targets by 2020 projected to reduce HIV incidence by ~50%
- Local elimination of HIV unlikely to occur in the next 20 years, even if NHAS targets met
- Future modelling should also consider the impact of increased PrEP coverage

- Large increases in viral suppression are needed to significantly reduce HIV incidence among Baltimore MSM
- Achieving NHAS targets by 2020 projected to reduce HIV incidence by ~50%
- Local elimination of HIV unlikely to occur in the next 20 years, even if NHAS targets met
- Future modelling should also consider the impact of increased PrEP coverage

- Large increases in viral suppression are needed to significantly reduce HIV incidence among Baltimore MSM
- Achieving NHAS targets by 2020 projected to reduce HIV incidence by ~50%
- **Local elimination of HIV unlikely to occur in the next 20 years, even if NHAS targets met**
- Future modelling should also consider the impact of increased PrEP coverage

- Large increases in viral suppression are needed to significantly reduce HIV incidence among Baltimore MSM
- Achieving NHAS targets by 2020 projected to reduce HIV incidence by ~50%
- Local elimination of HIV unlikely to occur in the next 20 years, even if NHAS targets met
- Future modelling should also consider the impact of increased PrEP coverage

- These results suggest ambitious targets for HPTN 078
  - Powered to detect an 18pp difference in viral suppression after 2 years → ~29% reduction incidence
  - 50% incidence reduction requires ~30pp difference
- Results suggest that other interventions may be needed in parallel with expanded treatment to reduce HIV incidence rapidly among US MSM

- These results suggest ambitious targets for HPTN 078
  - Powered to detect an 18pp difference in viral suppression after 2 years → ~29% reduction incidence
  - 50% incidence reduction requires ~30pp difference
- Results suggest that other interventions may be needed in parallel with expanded treatment to reduce HIV incidence rapidly among US MSM



# ACKNOWLEDGEMENTS

The HIV Prevention Trials Network is sponsored by the National Institute of Allergy and Infectious Diseases, the National Institute of Mental Health, and the National Institute on Drug Abuse, all components of the U.S. National Institutes of Health.

**The HPTN Modelling Centre is funded through the HPTN Statistical and Data Management Centre (UM1 AI068617)**

**HPTN Modelling Centre:** Marie-Claude Boily,  
Dobromir Dimitrov

**NHBS data:** Gabriela Paz-Bailey, Brooke Hoots, Danielle German, Colin Flynn

**HPTN 078:** Chris Beyrer, Robert Remien, Theresa Gamble, Protocol and site teams

